Symptom management for the adult patient dying with advanced chronic kidney disease: A review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group

Palliative Medicine

Volumn 23, Issue 2, 2009, Pages 103-110

  Douglas, Claire ^a   Murtagh, F E M ^b   Chambers, E J ^c   Howse, M ^d   Ellershaw, J ^e,f  

^a NINEWELLS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

^d ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f Marie Curie Palliative Care Institute   (United Kingdom)

Author keywords

Dying; Guidelines; Kidney disease; Opioids; Symptom management; Symptoms

Indexed keywords

ALFENTANIL; DIAMORPHINE; FENTANYL; GLYCOPYRRONIUM BROMIDE; HALOPERIDOL; HYDROMORPHONE; LEVOMEPROMAZINE; METOCLOPRAMIDE; MIDAZOLAM; MORPHINE; MORPHINE 6 GLUCURONIDE; NALOXONE; OPIATE; OXYCODONE; OXYMORPHONE; SCOPOLAMINE BUTYL BROMIDE;

AGITATION; BEHAVIOR DISORDER; BRONCHUS SECRETION; CHRONIC KIDNEY FAILURE; CONTINUOUS INFUSION; CREATININE CLEARANCE; DISEASE SEVERITY; DROWSINESS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYING; DYSPNEA; EVIDENCE BASED PRACTICE; EXTRAPYRAMIDAL SYMPTOM; GLOMERULUS FILTRATION RATE; HUMAN; LIFE EXPECTANCY; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NONHUMAN; PAIN; PALLIATIVE THERAPY; PARADOXICAL DRUG REACTION; PRACTICE GUIDELINE; RESPIRATION DEPRESSION; RESPIRATORY TRACT DISEASE; RESTLESSNESS; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SYMPTOMATOLOGY; TERMINAL CARE; TREATMENT INDICATION; UREMIA;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CONSENSUS; CRITICAL PATHWAYS; EVIDENCE-BASED MEDICINE; GREAT BRITAIN; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PATIENT SELECTION; TERMINAL CARE; YOUNG ADULT;

EID: 62549110025     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269216308100247     Document Type: Review

References (60)

1. Ansell D Feest T Rao R Williams A Winearls C. UK Renal Registry Report 2005. Bristol, UK: UK Renal Registry; 2006.
2. Roderick P Davies R Jones C Feest T Smith S Farrington K. Simulation model of renal replacement therapy: Predicting future demand in England. Nephrol Dial Transplant 2004; 19: 692-701.
3. Smith C Silva-Gane M Chandna S Warwicker P Greenwood R Farrington K. [see comment] Choosing not to dialyse: Evaluation of planned non-dialytic management in a cohort of patients with end-stage renal failure. Nephron Clin Pract 2003; 95: C40-c46.
4. Munshi SK Vijayakumar N Taub NA Bhullar H Lo TC Warwick G. Outcome of renal replacement therapy in the very elderly. Nephrol Dial Transplant 2001; 16: 128-133.
5. Murtagh FE Marsh JE Donohoe P Ekbal NJ Sheerin NS Harris FE. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant 2007; 22: 1955-1962.
6. Devins GM Armstrong SJ Mandin H Paul LC Hons RB Burgess ED. Recurrent pain, illness intrusiveness, and quality of life in end-stage renal disease. Pain 1990; 42: 279-285.
7. Cohen LM McCue JD Germain M Kjellstrand CM. Dialysis discontinuation. A 'good' death. Arch Intern Med 1995; 155: 42-49.
8. Cohen LM Germain M Poppel DM Woods A Kjellstrand CM. Dialysis discontinuation and palliative care. Am J Kidney Dis 2000; 36: 140-144.
9. Sprangers MA de Regt EB Andries F van Agt HM Bijl RV de Boer JB. Which chronic conditions are associated with better or poorer quality of life. J Clin Epidemiol 2000; 53: 895-907.
10. Department of Health. National Service Framework for Renal Services - Part 2; 2005.
11. J Ellershaw S Wilkinson,. Care of the dying: A pathway to excellence. Oxford: Oxford University Press; 2003.
12. Ellershaw J Ward C. Care of the dying patient: The last hours or days of life. BMJ 2003; 326: 30-34.
13. Jack C Jones L Jack BA Gambles M Murphy D Ellershaw JE. Towards a good death: The impact of the care of the dying pathway in an acute stroke unit. Age Ageing 2004; 33: 625- 626.
14. Doyle D Hanks G Cherny N Calman K. Oxford textbook of palliative medicine. 3rd ed. Oxford: Oxford University Press; 2004.
15. Chambers EJ Germain M Brown E. Supportive Care for the Renal Patient. 1st ed. Oxford: Oxford University Press; 2004.
16. Ashley C Currie A. The renal drug handbook. 2nd ed. Abingdon, UK: Radcliffe Medical Press Ltd; 2004.
17. Murtagh F Chai MO Donohoe P Edmonds P Higginson I. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother 2007; 21: 5-17.
18. http://www.renal.org/CKDguide/ckd.html
19. Cockcroft DW Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
20. Levey AS Bosch JP Lewis JB Greene T Rogers N Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
21. Murtagh F Addington-Hall J Higginson IJ. The prevalence of symptoms in end-stage renal disease: A systematic review. Adv Chronic Kidney Dis 2007; 14: 82-99.
22. Murtagh F Addington-Hall J Edmonds P Donohoe P Carey I Jenkins K. Symptoms in advanced renal disease - a cross-sectional survey of symptom prevalence in stage 5 chronic kidney disease managed without dialysis. J Palliat Med 2007;10: 1266-1276.
23. Cohen LM Germain MJ Poppel DM Woods AL Pekow PS Kjellstrand CM. Dying well after discontinuing the life-support treatment of dialysis. Arch Intern Med 2000; 160: 2513-2518.
24. Scottish Intercollegiate Guidelines Network. SIGN 50: A guideline developers handbook. Edinburgh: Scottish Intercollegiate Guidelines Network; 2001.
25. Mannix K. Palliation of nausea and vomiting. In: G Hanks N Cherny K Calman D Doyle, (eds). Oxford textbook of palliative medicine. 3rd ed. Oxford: Oxford University Press; 2005. p. 459-467.
26. Sirota RA Kimmel PL Trichtinger MD Diamond BF Stein HD Yudis M. Metoclopramide-induced parkinsonism in hemodialysis patients. Report of two cases. Arch Intern Med 1986; 146: 2070-2071.
27. May G Kumar R. Best evidence topic report. Use of intravenous cyclizine in cardiac chest pain. Emerg Med J 2006; 23: 61-62.
28. Kirvela M. Ali-Melkkila, t, Iisalo, E, Lindgren, L. Pharmacokinetics of Glycoyrronium in uraemic patients. Br J Anaesth 1993; 71: 437-439.
29. Ali-Melkkila T Kanto J Iisalo E. Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand 1993; 37: 633-642.
30. Bauer TM Ritz R Haberthur C Ha HR Hunkeler W Sleight AJ. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995; 346: 145-147.
31. Hanks GW Conno F Cherny N Hanna M Kalso E McQuay HJ. Morphine and alternative opioids in cancer pain: The EAPC recommendations. Br J Cancer 2001; 84: 587-593.
32. Aitkenhead AR Vater M Achola K Cooper CM Smith G. Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure. Br J Anaesth 1984; 56: 813-819.
33. Wolff J Bigler D Christensen CB Rasmussen SN Andersen HB Tonnesen KH. Influence of renal function on the elimination of morphine and morphine glucuronides. Eur J Clin Pharmacol 1988; 34: 353-357.
34. Sawe J Odar-Cederlof I. Kinetics of morphine in patients with renal failure. Eur J Clin Pharmacol 1987; 32: 377-382.
35. Angst MS Buhrer M Lotsch J. Insidious intoxication after morphine treatment in renal failure: Delayed onset of morphine-6-glucuronide action. Anesthesiology 2000; 92: 1473-1476.
36. Bodd E Jacobsen D Lund E Ripel A Morland J Wiik-Larsen E. Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure. Hum Exp Toxicol 1990; 9: 317-321.
37. Conway BR Fogarty DG Nelson WE Doherty CC. Opiate toxicity in patients with renal failure. BMJ 2006; 332: 345-346.
38. D'Honneur G Gilton A Sandouk P Scherrmann JM Duvaldestin P. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. Anesthesiology 1994; 81: 87-93.
39. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004; 28: 497-504.
40. Mercadante S Arcuri E. Opioids and renal function. J Pain 2004; 5: 2-19.
41. Heiskanen T Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 1997; 73: 37-45.
42. Mucci-LoRusso P Berman BS Silberstein PT Citron ML Bressler L Weinstein SM. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: A randomized, double-blind, parallel-group study. Eur J Pain 1998; 2: 239-249.
43. Foral PA Ineck JR Nystrom KK. Oxycodone Accumulation in a Hemodialysis Patient. South Med J 2007; 100: 212-214.
44. Fitzgerald J. Narcotic analgesics in renal failure. Conn Med 1991; 55: 701-704.
45. Broadbent A Khor K Heaney A. Palliation and chronic renal failure: opioid and other palliative medications - Dosage guidelines. Progress in Palliative Care. 2003; 11: 183-190.
46. Durnin C Hind ID Wickens MM Yates DB Molz KH. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment. Proc West Pharmacol Soc 2001; 44: 81-82.
47. Babul N Darke AC Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage 1995; 10: 184-186.
48. Lee MA Leng ME Tiernan EJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 2001; 15: 26-34.
49. Paix A Coleman A Lees J Grigson J Brooksbank M Thorne D. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain 1995; 63: 263-269.
50. Davies G Kingswood C Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996; 31: 410-422.
51. Coral IM Moore AR Strunin L. Plasma concentrations of fentanyl in normal surgical patients with severe renal failure. Br J Anaesth 1980; 52: 101P.
52. Labroo RB Paine MF Thummel KE Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: Implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997; 25: 1072-1080.
53. Koehntop DE Rodman JH. Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy 1997; 17: 746-752.
54. Alazia M Levron J.C. [Pharmacokinetic study of prolonged infusion of fentanyl in intensive care] Ann Fr Anesth Reanim 1987; 6: 465-466.
55. Bower S Hull CJ. Comparative pharmacokinetics of fentanyl and alfentanil. Br J Anaesth 1982; 54: 871-877.
56. Meuldermans W Van Peer A Hendrickx J Woestenborghs R Lauwers W Heykants J. Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology 1988; 69: 527-534.
57. Bower S Sear JW. Disposition of alfentanil in patients receiving a renal transplant. J Pharm Pharmacol 1989; 41: 654-657.
58. Chauvin M Lebrault C Levron JC Duvaldestin P. Pharmacokinetics of alfentanil in chronic renal failure. Anesth Analg 1987; 66: 53-56.
59. http://www.mcpcil.org.uk/liverpool_care_pathway
60. Ansell D Roderick P Hodsman A Steenkamp R Tomson C. Survival of incident and prevalent patients. In: D Ansell J Feehally TG Feest C Tomson AJ Williams G Warwick, (eds), UK Renal Registry Report 2007. Bristol, UK: UK Renal Registry. 2007. p. 93-119. [chapter 6]